Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06990867 | Optimizing Reperfusion to Improve Outcomes and Neurologic Function | PHASE2 | RECRUITING | 740 | — | — | May 15, 2025 | Dec 31, 2029 | Mar 13, 2026 | 83 | United States, Belgium +16 |
| Arm | Type | Description |
|---|---|---|
| Part 1 - JX10 (1mg/kg) | EXPERIMENTAL | - |
| Part 1 - JX10 (3mg/kg) | EXPERIMENTAL | - |
| Part 1 - Placebo | PLACEBO_COMPARATOR | - |
| JX10 Part 2 - (1 or 3 mg/kg) | EXPERIMENTAL | - |
| Part 2 - Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JX10 | DRUG | JX10 is a thrombolytic agent. |
| Placebo | DRUG | Placebo is being used as the comparator. |
Inclusion Criteria: 1. Age ≥ 18 and ≤ 90 years old. 2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or...